Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Prednisone

    go.drugbank.com/drugs/DB00635
    ApprovedInvestigationalVet approved

    [A187463] It is biologically inert and converted to [prednisolone] in the liver.[L10502] Prednisone was granted FDA approval on 21 February 1955.[L10496]

  2. Drug

    Phenmetrazine

    go.drugbank.com/drugs/DB00830
    ApprovedIllicit

    A sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.

  3. Drug

    Brexpiprazole

    go.drugbank.com/drugs/DB09128
    ApprovedInvestigational

    [A182186] Currently approved for the treatment of depression, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease, brexpiprazole has also been investigated in other psychiatric … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.

  4. Drug

    Baclofen

    go.drugbank.com/drugs/DB00181
    ApprovedInvestigational

    Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.

  5. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. … Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone].

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcSynonyms: N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
  6. Drug

    Misoprostol

    go.drugbank.com/drugs/DB00929
    ApprovedInvestigational

    [L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the … [A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616]

  7. Drug

    Donepezil

    go.drugbank.com/drugs/DB00843
    ApprovedInvestigational

    Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia. … [A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage

    Products: DONEPEZIL WIN MEDICA
  8. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. … [L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]

  9. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    It was FDA approved in October 2018. … Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults.

  10. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].

    Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers